These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15549012)

  • 1. A nurse-led, patient-centred mitoxantrone service in neurology.
    Harrison E; Porter B
    Br J Nurs; 2004 Sep 23-Oct 13; 13(17):1021-3. PubMed ID: 15549012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone in the treatment of multiple sclerosis.
    Morrissey SP; Le Page E; Edan G
    Int MS J; 2005 Nov; 12(3):74-87. PubMed ID: 16417821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mitoxantrone, a new reality].
    Ruiz-Peña JL; Izquierdo G
    Rev Neurol; 2003 Apr 1-15; 36(7):698-9. PubMed ID: 12666055
    [No Abstract]   [Full Text] [Related]  

  • 5. Mitoxantrone immunotherapy in multiple sclerosis.
    Gonsette RE
    Mult Scler; 1996 Jul; 1(6):329-32. PubMed ID: 9345411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Adv Neurol; 2006; 98():293-302. PubMed ID: 16400840
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting.
    Wundes A; Kraft GH; Bowen JD; Gooley TA; Nash RA
    Clin Neurol Neurosurg; 2010 Dec; 112(10):876-82. PubMed ID: 20727669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Ellis R; Brown S; Boggild M
    Mult Scler; 2015 Apr; 21(5):642-5. PubMed ID: 25013152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mitoxanthrone in the therapy of multiple sclerosis].
    Kieseier BC; Gold R; Hartung HP
    Nervenarzt; 2003 Oct; 74(10):906-10. PubMed ID: 14551698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
    Jamroz-Wisniewska A; Beltowski J; Stelmasiak Z; Bartosik-Psujek H
    Acta Neurol Scand; 2013 Jun; 127(6):e33-6. PubMed ID: 22881373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunosuppressive therapy of multiple sclerosis with mitoxantrone].
    Mauch E; Kornhuber HH
    Fortschr Neurol Psychiatr; 1993 Dec; 61(12):410-7. PubMed ID: 8112704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Article on mitoxantrone-induced extravasation raised useful questions.
    Schulmeister L
    Oncol Nurs Forum; 2005 Jul; 32(4):719-20. PubMed ID: 15997519
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Pattoneri P; Pelà G; Montanari E; Pesci I; Moruzzi P; Borghetti A
    Eur J Echocardiogr; 2007 Mar; 8(2):144-50. PubMed ID: 16603413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis.
    Mogenet I; Simiand-Erdociain E; Canonge JM; Pris J
    Ann Pharmacother; 2003 May; 37(5):747-8. PubMed ID: 12708958
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis: current treatment algorithms.
    Río J; Comabella M; Montalban X
    Curr Opin Neurol; 2011 Jun; 24(3):230-7. PubMed ID: 21499098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukaemia due to mitoxantrone.
    Prescrire Int; 2007 Aug; 16(90):153-6. PubMed ID: 17724842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BLOOD COUNT IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH MITOXANTRONE IN SHORT TIME OBSERVATION.
    Pastuszak Z; Stepien A; Tomczykiewicz K; Piusinska-Macoch R
    Acta Pol Pharm; 2016 Sep; 73(5):1369-1373. PubMed ID: 29638077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.